InvestorsHub Logo
icon url

doogdilinger

02/02/15 9:28 AM

#9857 RE: nccmtt #9853

Ahhhhhhhh you could be onto something there nccmtt...my only question is the language used in the PR which specifically states "exclusive".

Not sure how that affects IPCI's already existing deal with PAR as it doesn't seem likely that PAR would give up its exclusivity on the other FocalinXR strengths but only IPCI, PAR and TEVA truly know right!

Good speculation on your part...and worthy of further discussion!
icon url

Thedrugguru

02/02/15 9:34 AM

#9858 RE: nccmtt #9853

Matteo, excellent point. TEva has had problems manufacturing Focalin XR but not IPCI.